

Subject: Medical Policy Formation

Document #: ADMIN.00001

Status: Revised

Publish Date: 01/03/2024

Last Review Date: 11/09/2023

Description/Scope

The Office of Medical Policy & Technology Assessment (OMPTA) develops medical policy and clinical utilization management (UM) guidelines (collectively, "Medical Policy") for the company. The principal component of the process is the review for development of medical necessity and/or investigational and not medically necessary position statements or clinical indications that are objective and based on medical evidence for certain new medical services and/or procedures or for new uses of existing services and/or procedures. The services consisting of medical, surgical, and behavioral health treatments, may include, but are not limited to devices, biologics, specialty pharmaceuticals, gene therapies, and professional health services.

Medical Policies are intended to reflect current scientific data and clinical thinking. While Medical Policy sets forth position statements or clinical indications regarding the medical necessity of individual services and/or procedures, Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage.

The Medical Policy & Technology Assessment Committee (MPTAC) is a multiple disciplinary group including physicians from various medical and behavioral health specialties, clinical practice environments and geographic areas. Voting membership may include:

- External physicians in clinical practices and participating in networks;
- External physicians in academic practices and participating in networks;
- Internal medical directors;
- Chairs of MPTAC Subcommittees.

Non-voting members may include:

- Internal legal counsel;
- Internal medical directors.

MPTAC meets at least three times per year. Agenda topics are identified, researched, updated, collated and distributed to the committee. Input from the medical community is solicited and utilized in developing and updating criteria. In addition, agenda items are identified from, but not limited to: clinical literature, medical operations associates, medical directors, claims operations, external reviews, technology vendors, and other technology assessment entities. Decisions are made by a majority vote of MPTAC voting members present. Majority representation of the voting committee members must be present to constitute a quorum. MPTAC may designate subcommittees when needed, which may include internal or external physicians. The subcommittees shall make recommendations to MPTAC on topics assigned to them by MPTAC.

MPTAC voting members and subcommittee members are required to disclose any potential conflicts of interest. In the event that a MPTAC voting member or subcommittee member discloses a conflict of interest, the associated member will not participate in the vote specific to the proposed relevant Medical Policy.

To reach decisions regarding the medical necessity or investigational status of new or existing services and/or procedures, MPTAC (and its applicable subcommittees) relies on the medical necessity or investigational criteria included in the following policies:

- [ADMIN.00004 Medical Necessity Criteria](#)
- [ADMIN.00005 Investigational Criteria](#)

In evaluating the medical necessity or investigational status of new or existing services and/or procedures the committee(s) may include, but not limit their consideration to, the following additional information provided to committee members:

- Collated results of electronic literature searches;
- Independent technology evaluation programs and materials published by professional associations, such as:
 - Technology assessment entities;
 - Appropriate government regulatory bodies; and
 - National physician specialty societies and associations.

When reviewing the results of electronic literature searches, the committee may consider study methodology, including but not limited to features such as randomization, blinding, clinically appropriate follow-up periods, and use of validated and objective measurement tools. The committee will also consider whether studies provide credible scientific evidence which permits reasonable conclusions regarding net health outcomes (balance of safety and efficacy) and appropriate comparisons to established alternatives. The literature discussed and included in policy documents should not be construed to represent all of the scientific evidence available on a topic or reviewed in policy development. Publications such as review articles, white papers, case studies, abstracts, and articles not published in medical journals indexed in the National Library of Medicine's PubMed database are typically not included in policy documents.

The committee(s) may also consider the service/procedure being reviewed as a standard of care in the medical community with supporting documentation.

The committee(s) is also responsible for reviewing and authorizing the use of clinical utilization management guidelines used as the standard Enterprise-wide solution for making determinations of medical necessity which are developed by external entities (for example, MCG care guidelines).

Additionally, for topics deemed to represent a significant change or as otherwise required by law or accreditation, the OMPTA team seeks additional input from selected experienced clinicians. This process allows MPTAC access to the expertise of a wide variety of specialists and subspecialists from across the United States. These individuals are board certified providers who are identified either with the assistance of an appropriate professional medical specialty society, by activity in a participating academic medical center or by participation in a corporate affiliated network. While the various professional medical societies may collaborate in this process through the provision of appropriate reviewers, the input received represents NEITHER an endorsement by the specialty society NOR

an official position of the specialty society. MPTAC uses this information in the context of all other information presented from various sources.

Medical Policy may be developed and approved or revised between scheduled MPTAC meetings when there is a need to do so prior to the next scheduled meeting of MPTAC. The research associates of OMPTA will develop the draft Medical Policy and request input from appropriate consultant providers, and if applicable, the relevant subcommittee. An ad-hoc interim MPTAC meeting or vote is scheduled to review and vote on the proposed interim Medical Policy. Policies presented on an interim basis (whether approved, modified or rejected) may be presented for full review and discussion at the next scheduled MPTAC meeting when additional committee input is required (for example, additional clinical input is received).

In the absence of specific Medical Policy, case-by-case individual review is undertaken. A physician designated by the health plan will review the request using the technology assessment criteria and appropriate standards that may include, but are not limited to, any of the following: peer-reviewed literature, other organizations' technology evaluations, Agency for Healthcare Research and Quality (AHRQ), various medical specialty societies' guidelines and assessments, and the clinician's professional judgment. Refer to the following document for additional information: ADMIN.00006 Review of Services for Benefit Determinations in the Absence of a Company Applicable Medical Policy or Clinical Utilization Management (UM) Guideline.

All existing Medical Policies are reviewed at least annually through MPTAC to determine continued applicability, appropriateness, and whether there is a need for revision, updates to citations, or other changes.

Medical Policies approved by MPTAC are also communicated throughout the company for inclusion in the benefit plan and for implementation of supporting processes. These communication processes include:

- Attendance of key associates at MPTAC meetings;
- Teleconferences with and written documentation to medical operations associates, medical directors, claims and network relations associates;
- Provision of MPTAC meeting minutes and other relevant documentation to health plan leadership.

Medical Policy decisions affecting our members are reported by our health plans to and reviewed for input by the appropriate physician quality committees, which have the responsibility for reviewing MPTAC activities.

Index

Medical Policy & Technology Assessment Committee
MPTAC
Office of Medical Policy & Technology Assessment
OMPTA
MCG guidelines

Document History

Status	Date	Action
Revised	11/09/2023	Medical Policy & Technology Assessment Committee (MPTAC) review. Revised grammar and spacing issues.
Revised	11/10/2022	MPTAC review. Revised text related to review and authorization of documents developed by external entities.
Reviewed	11/11/2021	MPTAC review.
Revised	11/05/2020	MPTAC review. Added text in Scope section regarding evidence review process.
Reviewed	08/13/2020	MPTAC review.
Revised	11/07/2019	MPTAC review. Updated text in Scope regarding services addressed and subspecialty committees.
Revised	11/08/2018	MPTAC review. Updated Description/Scope section concerning MPTAC membership to include BH specialists. Updated text regarding subspecialty committees, including removal of BH subcommittee. Clarified TPC subcommittee may include BH specialists. Updated Index section.
Revised	01/25/2018	MPTAC review. Updated Description/Scope concerning MPTAC and subspecialty committee voting membership, clarified that non-voting members may include internal medical directors, added details regarding third party criteria subcommittee, and revised text related to topics brought to interim meetings.
Revised	11/02/2017	MPTAC review. The document header wording updated from "Current Effective Date" to "Publish Date." Clarification made in the Description/Scope section.
Revised	02/02/2017	MPTAC review. Minor typographical revisions made to the Description section.
Reviewed	02/04/2016	MPTAC review.
Revised	02/05/2015	MPTAC review. Clarifications to the Description/Scope section.
Revised	02/13/2014	MPTAC review. Updated Description/Scope concerning MPTAC voting membership and specialist/practitioner involvement in the MPTAC decision-making process.
Revised	08/08/2013	MPTAC review. Updates to the Description/Scope to include a statement addressing committee(s) responsibility for reviewing and authorizing the use of Medical Policy. Additional format revisions and clarifications throughout the document.
Revised	08/09/2012	MPTAC review. Clarifications to the Description section with reference to ADMIN.00004 and ADMIN.00005.
Revised	11/17/2011	MPTAC review. Clarified names of specific departments within the organization. Revised wording throughout the document including the annual review process statement.
Revised	11/18/2010	MPTAC review. Addition of acronyms for specific organizations including the Office of Medical Policy & Technology Assessment (OMPTA) to the Description/Scope and Index. Revised title for ADMIN.00006 to Review of Services for Benefit Determinations in the Absence of a Company Applicable Medical Policy or Clinical Utilization Management (UM) Guideline.
Reviewed	11/19/2009	MPTAC review.
Reviewed	11/20/2008	MPTAC review. Removed the word experimental from the Description/Scope statement.
Revised	11/29/2007	MPTAC review. Addition of reference to subcommittees.

Revised	12/07/2006	MPTAC review. Clarification to wording and removal of procedural information.
Revised	12/01/2005	MPTAC review. Reference to ADMIN.00006 added; deleted Hayes, Inc. as reference when there is no medical policy or clinical guideline available.
Revised	09/22/2005	MPTAC review. 1. Included statement regarding MPTAC voting member's requirement to disclose potential conflicts of interest and the recusal of their associated vote on the relevant medical policy where a conflict of interest has been disclosed. 2. Modified wording specific to the section beginning "In the absence of specific medical policy..." to align with the Settlement Agreement requirements on Initial Determinations (7.14 a).
Reviewed	07/14/2005	MPTAC review. Revision based on Pre-merger Anthem and Pre-merger WellPoint Harmonization.

Pre-Merger Organizations	Last Review Date	Document Number	Title
Anthem, Inc.		No prior document	
WellPoint Health Networks, Inc.	09/23/2004		Medical Policy and Technology Assessment – Policy Formation

Applicable to Commercial HMO members in California: When a medical policy states a procedure or treatment is investigational, PMGs should not approve or deny the request. Instead, please fax the request to Anthem Blue Cross Grievance and Appeals at fax # 818-234-2767 or 818-234-3824. For questions, call G&A at 1-800-365-0609 and ask to speak with the Investigational Review Nurse.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association